<table>
<thead>
<tr>
<th>Drug name</th>
<th>Screen concentration</th>
<th>Category*</th>
<th>Clinical use</th>
<th>Known target(s)</th>
<th>references</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate</td>
<td>60nM</td>
<td>Antimetabolites / Immunosuppressants</td>
<td>Antineoplastic</td>
<td>DHFR</td>
<td>Vander Heiden 2011</td>
</tr>
<tr>
<td>Aminopterin</td>
<td>20nM</td>
<td>Antimetabolites (discontinued)</td>
<td>Dermatologic agent (phase I) Antineoplastic agent (phase II)</td>
<td>DHFR, FPGS(?)</td>
<td>Farber 1948</td>
</tr>
<tr>
<td>Orlistat</td>
<td>20μM</td>
<td>Antiobesity preparations, excl. diet products</td>
<td>Anti-obesity agent</td>
<td>LPL PNLIP FASN</td>
<td>Shi 2004</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>1μM</td>
<td>Cytotoxic antibiotics and related substances</td>
<td>Antineoplastic agent</td>
<td>DNA LIG1 LIG3</td>
<td>Chen 2005</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>2μM</td>
<td>Other antineoplastic agents</td>
<td>Antineoplastic agent</td>
<td>DNA</td>
<td>Kelland 2007</td>
</tr>
<tr>
<td>Mitomycin C</td>
<td>80nM</td>
<td>Cytotoxic antibiotics and related substances</td>
<td>Antineoplastic agent</td>
<td>DNA</td>
<td>Iyer 1963</td>
</tr>
<tr>
<td>17_DMAG</td>
<td>70nM</td>
<td>Experimental Hsp90 inhibitor</td>
<td>Antineoplastic agent (phases I &amp; II)</td>
<td>Hsp90 HSP90AA1 HSP90AA2 HSP90B1 HSP90AB1</td>
<td>Egorin 2002</td>
</tr>
</tbody>
</table>

*Anatomical Therapeutic Chemical Classification System

Table 1. Characteristics of screened compounds.